Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients
Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...
| Main Authors: | , , , , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Elsevier
2023-12-01
|
| 丛编: | Translational Oncology |
| 主题: | |
| 在线阅读: | http://www.sciencedirect.com/science/article/pii/S1936523323001857 |
| _version_ | 1827791749978783744 |
|---|---|
| author | Katarina Mirjačić Martinović Ana Vuletić Nevena Tišma Miletić Irina Besu Žižak Jelena Milovanović Suzana Matković Vladimir Jurišić |
| author_facet | Katarina Mirjačić Martinović Ana Vuletić Nevena Tišma Miletić Irina Besu Žižak Jelena Milovanović Suzana Matković Vladimir Jurišić |
| author_sort | Katarina Mirjačić Martinović |
| collection | DOAJ |
| description | Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods: The levels of TGF-β, IFN-γ, IL-6, IL-8, IL-10 were measured in sera and plasma by ELISA method of 30 healthy controls (HC) and 32 BRAF wild type (wt) MM patients before and after every 12 weeks of Pembrolizumab, PD-1 inhibitor, until one year or disease progression (DP). Results: Higher pretherapy levels of circulating TGF-β, IFN-γ, IL-6, and IL-10 were shown in MM patients compared to HC. In patients with disease control, TGF-β and IL-6 first decreased during the therapy, while then they started to successively increase reaching the initial values by the end of the follow up. Furthermore, in this group of patients IFN-γ increased, while IL-8 and IL-10 decreased at final points of the follow up. In patients with DP IL-6 increased at the time of progression, while IL-8 decreased when the best response was achieved. In patients with pseudoprogression IL-6 and IL-10 significantly increased compared to the pretreatment values. Melanoma patients with irAEs had increased baseline values of TGF-β, IFN-γ, IL-6, and IL-10 compared to HC. However, no significant changes in cytokines levels were found in these patients during therapy. Conclusions: Inflammatory cytokines monitoring in circulation of BRAFwt MM patients could help in the selection of patients who will have the benefit from Pembrolizumab therapy. |
| first_indexed | 2024-03-11T17:51:19Z |
| format | Article |
| id | doaj.art-c68b01a901b24440bc1d7b0973b2c6f9 |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-03-11T17:51:19Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-c68b01a901b24440bc1d7b0973b2c6f92023-10-18T04:30:56ZengElsevierTranslational Oncology1936-52332023-12-0138101799Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patientsKatarina Mirjačić Martinović0Ana Vuletić1Nevena Tišma Miletić2Irina Besu Žižak3Jelena Milovanović4Suzana Matković5Vladimir Jurišić6Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, Serbia; Corresponding author.Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, SerbiaDepartment of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, SerbiaDepartment of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, SerbiaDepartment of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, SerbiaDepartment of Medical Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, Belgrade 11000, SerbiaFaculty of Medical Sciences, University of Kragujevac, P.BOX 124, Kragujevac 34 000, SerbiaBackground: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods: The levels of TGF-β, IFN-γ, IL-6, IL-8, IL-10 were measured in sera and plasma by ELISA method of 30 healthy controls (HC) and 32 BRAF wild type (wt) MM patients before and after every 12 weeks of Pembrolizumab, PD-1 inhibitor, until one year or disease progression (DP). Results: Higher pretherapy levels of circulating TGF-β, IFN-γ, IL-6, and IL-10 were shown in MM patients compared to HC. In patients with disease control, TGF-β and IL-6 first decreased during the therapy, while then they started to successively increase reaching the initial values by the end of the follow up. Furthermore, in this group of patients IFN-γ increased, while IL-8 and IL-10 decreased at final points of the follow up. In patients with DP IL-6 increased at the time of progression, while IL-8 decreased when the best response was achieved. In patients with pseudoprogression IL-6 and IL-10 significantly increased compared to the pretreatment values. Melanoma patients with irAEs had increased baseline values of TGF-β, IFN-γ, IL-6, and IL-10 compared to HC. However, no significant changes in cytokines levels were found in these patients during therapy. Conclusions: Inflammatory cytokines monitoring in circulation of BRAFwt MM patients could help in the selection of patients who will have the benefit from Pembrolizumab therapy.http://www.sciencedirect.com/science/article/pii/S1936523323001857Metastatic melanoma patientsBRAF wild typePembrolizumabCytokinesMonitoringOutcome predictors |
| spellingShingle | Katarina Mirjačić Martinović Ana Vuletić Nevena Tišma Miletić Irina Besu Žižak Jelena Milovanović Suzana Matković Vladimir Jurišić Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients Translational Oncology Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors |
| title | Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients |
| title_full | Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients |
| title_fullStr | Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients |
| title_full_unstemmed | Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients |
| title_short | Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients |
| title_sort | circulating cytokine dynamics as potential biomarker of response to anti pd 1 immunotherapy in brafwt mm patients |
| topic | Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors |
| url | http://www.sciencedirect.com/science/article/pii/S1936523323001857 |
| work_keys_str_mv | AT katarinamirjacicmartinovic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT anavuletic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT nevenatismamiletic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT irinabesuzizak circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT jelenamilovanovic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT suzanamatkovic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients AT vladimirjurisic circulatingcytokinedynamicsaspotentialbiomarkerofresponsetoantipd1immunotherapyinbrafwtmmpatients |